Swart P J, Harmsen M C, Kuipers M E, Van Dijk A A, Van Der Strate B W, Van Berkel P H, Nuijens J H, Smit C, Witvrouw M, De Clercq E, de Béthune M P, Pauwels R, Meijer D K
Groningen University Institute for Drug Exploration, Department of Pharmacokinetics and Drug Delivery, University Centre for Pharmacy, The Netherlands.
J Pept Sci. 1999 Dec;5(12):563-76. doi: 10.1002/(SICI)1099-1387(199912)5:12<563::AID-PSC226>3.0.CO;2-3.
Previous studies have shown that acylated plasma and milk proteins with increased negative charge, derived from various animal and human sources, are potent anti-HIV compounds. The antiviral effects seemed to correlate positively with the number of negative charges introduced into the various polypeptides: proteins with a high content of basic amino acids in which all of the available epsilonNH2 groups were anionized yielded the most potent anti-HIV compounds. It remained unclear however whether the total net negative charge of the various derivatized proteins, or rather the charge density on the protein backbone, is essential for the observed anti-HIV activity. Earlier studies have shown that acylated albumins preferentially block the process of HIV/cell fusion through binding to the HIV envelope proteins gp120 and gp41 as well as to the cell surface of the HIV target cells. Some of these polyanionic proteins have been shown to interfere also with the gp120-CD4 mediated virus/cell binding. The relative contribution of these effects to the anti-HIV activity may depend both on the total negative charge introduced as well as the hydrophobicity of the acylating reagent added to the particular proteins. In this study we show that the higher the charge density of the derivatized proteins, the more potent their HIV replication inhibiting effects are. In contrast, the addition of positive charge to the studied plasma and milk proteins through amination resulted in a reduced anti-HIV activity but a clearly increased anti-HCMV activity, with IC50 values in the low micromolar concentration range. Interestingly, native lactoferrin (Lf) was antivirally active against both HIV and HCMV. Acylation or amination of Lf increased the anti-HIV and anti-HCMV activity, respectively. The N-terminal portion of Lf appeared essential for its anti-HCMV effect: N-terminal deletion variants of human Lf were less active against HCMV. Circular dichroism of the modified proteins showed that the secondary structure of the tested proteins was only moderately influenced by acylation and/or covalent attachment of drugs, making these (derivatized) proteins useful candidates as antiviral agents and/or intrinsically active drug carriers. The relatively simple chemical derivatization as well as the abundant sources of blood plasma and milk proteins provides attractive opportunities for the preparation of potent and relatively cheap antiviral agents for systemic or local applications.
先前的研究表明,源自各种动物和人类来源的、带负电荷增加的酰化血浆蛋白和乳蛋白是有效的抗HIV化合物。抗病毒效果似乎与引入各种多肽中的负电荷数量呈正相关:碱性氨基酸含量高且所有可用的ε-NH₂基团都被阴离子化的蛋白质产生的抗HIV化合物效力最强。然而,尚不清楚各种衍生化蛋白质的总净负电荷,还是蛋白质主链上的电荷密度对于观察到的抗HIV活性至关重要。早期研究表明,酰化白蛋白通过与HIV包膜蛋白gp120和gp41以及HIV靶细胞的细胞表面结合,优先阻断HIV/细胞融合过程。其中一些聚阴离子蛋白也被证明会干扰gp120-CD4介导的病毒/细胞结合。这些作用对抗HIV活性的相对贡献可能既取决于引入的总负电荷,也取决于添加到特定蛋白质中的酰化试剂的疏水性。在本研究中,我们表明衍生化蛋白质的电荷密度越高,其抑制HIV复制的效果就越强。相反,通过胺化向所研究的血浆蛋白和乳蛋白中添加正电荷会导致抗HIV活性降低,但抗HCMV活性明显增加,IC50值在低微摩尔浓度范围内。有趣的是,天然乳铁蛋白(Lf)对HIV和HCMV均具有抗病毒活性。Lf的酰化或胺化分别增加了其抗HIV和抗HCMV活性。Lf的N端部分似乎对其抗HCMV作用至关重要:人Lf的N端缺失变体对HCMV的活性较低。修饰后蛋白质的圆二色性表明,测试蛋白质的二级结构仅受到酰化和/或药物共价连接的适度影响,这使得这些(衍生化)蛋白质成为抗病毒剂和/或内在活性药物载体的有用候选物。相对简单的化学衍生化以及血浆蛋白和乳蛋白的丰富来源为制备用于全身或局部应用的强效且相对便宜的抗病毒剂提供了有吸引力的机会。